Previous 10 | Next 10 |
LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the initation of a U.S. clinical trial evaluating the performance of its T2Biothreat® Panel designed to support a submissi...
LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the initiation of a U.S. multi-site clinical trial evaluating the performance of its T2Resistance ® Panel designed to ...
T2 Biosystems (NASDAQ:TTOO) perks up 3.3% premarket after announcing that its T2SARS-CoV-2 Panel detects the Omicron COVID-19 variant (B.1.1.529). To confirm that the T2SARS-CoV-2 Panel would detect the new variant, in silico analysis was performed using sequences in the GISAID data...
LEXINGTON, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that its T2SARS-CoV-2™ Panel detects the Omicron COVID-19 variant (B.1.1.529). The World Health Organizat...
LEXINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the execution of a territory exclusive distribution agreement in Taiwan. Under the terms of the agreement, T2 Biosys...
LEXINGTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced plans to participate in the upcoming Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Foru...
LEXINGTON, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced it will participate in the 7 th annual World Anti-Microbial Resistance Congress (WAMR) taking place on November 8 and 9 in Washin...
T2 Biosystems, Inc. (TTOO) Q3 2021 Results Earnings Conference Call November 04, 2021, 04:30 PM ET Company Participants Philip Taylor - Investor Relations. John Sperzel - Chairman & CEO John Sprague - CFO Conference Call Participants Presentation Operator Good afternoon, and welcome to th...
T2 Biosystems (NASDAQ:TTOO): Q3 GAAP EPS of -$0.08 beats by $0.01. Revenue of $7.43M (+41.5% Y/Y) beats by $1.63M. Shares +4%. Press Release The Company is raising its revenue expectations to reflect its third quarter results and now expects revenue for the full year 2021 to be between $25.0 ...
T2 Biosystems (NASDAQ:TTOO) announces the appointment of Brett Giffin as its Chief Commercial Officer, effective November 8, 2021. Giffin brings a wealth of industry experience and commercial leadership to T2 Biosystems, having served as Chief Executive Officer for two early st...
News, Short Squeeze, Breakout and More Instantly...
LEXINGTON, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the second quarter 2024 and business updates after mar...
2024-07-18 04:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
LEXINGTON, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a territory exclusive distribution agreement in Hong Kong and Macau. Under the terms ...